Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Key Highlights for Investors

• First Patient Dosed in Phase IIa Trial: Oragenics (NYSE American: OGEN) has successfully dosed its first patient with ONP-002 at Mackay Base Hospital, Australia, marking the official commencement of the company’s Phase IIa clinical trial for mild traumatic brain injury (mTBI), commonly known as concussion.
• Strong Enrollment Velocity: The first patient was enrolled within days of the site activation on March 31, 2026, indicating significant unmet medical need and potentially rapid trial enrollment.
• Potentially Transformative Therapy: If approved, ONP-002 could become the first and only FDA-approved pharmacological treatment for concussion, addressing a market with no current drug therapies and a global incidence of approximately 69 million cases annually.
• Expanding Clinical Footprint: Additional trial sites at Alfred Hospital (Melbourne) and Royal Adelaide Hospital (Adelaide) in Australia are progressing through activation, expected in Q2 2026.
• Innovative Drug Delivery: ONP-002 is a first-in-class neurosteroid delivered via a proprietary intranasal spray-dry powder device, targeting neuroinflammation, oxidative stress, and cerebral edema, shifting the paradigm from symptom management to active neurological intervention.
• Strong Safety Profile: Phase 1 trials demonstrated safety and tolerability across all dose levels in 40 patients, with zero serious adverse events, supporting advancement to Phase IIa.
• Significant Market Potential: The global concussion market is projected to exceed \$9 billion by 2030, while the broader nasal drug delivery market could reach nearly \$93 billion in the same timeframe.
• Regulatory and Operational Milestones: The company plans to leverage Phase IIa data for an investigational new drug (IND) application submission to the FDA by Q4 2026, paving the way for U.S. Phase IIb trials.

Details and Analysis

Oragenics’ latest announcement marks a pivotal moment for the company and shareholders, as the Phase IIa clinical trial for ONP-002, targeting mild traumatic brain injury (mTBI), is now officially underway. The trial’s first patient was dosed at Mackay Base Hospital, Australia, only days after the site’s activation. This swift enrollment underscores both the substantial unmet medical need and the operational readiness of Oragenics’ clinical team.

Concussions, or mTBI, are among the most prevalent neurological conditions without any FDA-approved pharmacological intervention. The U.S. sees an estimated 1.7–3.8 million traumatic brain injuries annually, with sports and recreational activities as leading causes. Globally, approximately 69 million individuals sustain traumatic brain injuries each year. Currently, patients—ranging from athletes to military personnel—have few options besides rest and symptom management. If ONP-002 receives approval, it could completely transform the standard of care in this widespread, high-need market.

Market Opportunity and Competitive Edge

The global concussion therapy market is projected to reach over \$9 billion by 2030. Additionally, Oragenics’ proprietary nasal drug delivery platform positions the company within a rapidly growing market segment, expected to hit nearly \$93 billion by 2030. ONP-002’s intranasal, neuroprotective approach not only offers rapid, targeted delivery to the brain but also differentiates itself from competitors focused solely on symptom management.

Clinical Trial Design and Next Steps

• The Phase IIa trial is a randomized, placebo-controlled study enrolling 40 patients who meet eligibility criteria based on CT scan findings, symptoms, and hospital admission.
• Patients will receive ONP-002 or placebo within 12 hours of injury, with continued dosing for up to 30 days, followed by comprehensive safety, tolerability, and neurocognitive assessments.
• Key endpoints include safety, tolerability, feasibility, and participant compliance.
• Southern Star Research, an established Australian CRO, is managing trial operations, while Sterling Pharma Solutions is providing cGMP drug manufacturing from North Carolina, U.S.
• Data from this trial will support an IND application to the FDA, targeted for Q4 2026, which is a critical regulatory milestone for advancing to larger U.S.-based trials.

Management Commentary

Janet Huffman, CEO: “We said we would dose our first patient in Australia — and we have. Mackay Hospital was active for only a matter of days before an eligible patient presented, and that immediacy is not a coincidence. It reflects the reality of what we have always said: there is no pharmacological treatment for concussion, and patients and clinicians are ready for something new. Site activation was swift and now the trial is underway. We are executing, and we intend to keep executing. For the millions of people who suffer concussions every year and are told there is nothing that can be done — we are here to change that.”

Dr. James Kelly, CMO: “The Phase 1 safety profile gave us strong scientific confidence entering this next phase. The HREC process is rigorous by design — it exists to protect patients, and receiving that clearance confirmed that our trial design, safety protocols, and investigator teams meet the highest standards. As a clinician who has worked with concussion patients for decades, this moment is deeply meaningful. ONP-002 targets the injury itself, not just the symptoms. That is a fundamentally different approach to concussion care, and we are now putting it to the test in patients.”

Clinical Foundation

The Phase 1 trial of ONP-002 reported zero serious adverse events across all dose levels in 40 patients, supporting its advancement to Phase IIa. Preclinical data demonstrated reductions in brain swelling, inflammation, and oxidative stress, as well as improved functional recovery—key scientific credentials that underpin the drug’s potential.

Oragenics’ Broader Strategy

Oragenics is positioning its proprietary intranasal drug delivery platform for applications beyond concussion, including Parkinson’s and Alzheimer’s disease, signaling a pipeline approach targeting significant unmet needs in neurological care.

Potential Share Price Catalysts and Risks

• Positive Clinical Progress: Rapid enrollment and trial initiation could boost investor confidence and share price, given the high unmet need and large addressable market.
• Regulatory Milestones: Successful completion of Phase IIa and subsequent IND submission will be closely watched as major catalysts.
• First-Mover Advantage: If ONP-002 is approved, Oragenics would be the first to market with a pharmacological therapy for concussion, potentially commanding significant market share.
• Risks: As with all clinical-stage companies, outcomes are subject to regulatory risk, trial data uncertainties, and execution risks. Investors should monitor progress on site activations, enrollment rates, and safety/tolerability data announcements.

Investor Relations Contact

For further information, please contact Oragenics Investor & Media Relations:
ICR Inc.
800-383-4880
[email protected]

Disclaimer

This article includes forward-looking statements based on current management assumptions and available information as of the date of publication. Actual results could differ materially due to risks and uncertainties, including but not limited to, clinical development, regulatory approvals, market acceptance, and company execution. Investors are cautioned not to place undue reliance on these statements and should review Oragenics’ filings with the SEC for additional risk factors. The author assumes no obligation to update these statements as circumstances change.

View ORAGENICS INC Historical chart here